Project Grant R01CA301585
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $642K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- The National Cancer Institute awarded the University of Washington $686,271 on May 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to support proteomics-driven analysis and robotics-enabled drug testing of microdissected tumors and their microenvironment. The funded work develops high-throughput approaches to rapidly dissect thousands of regularly-sized microdissected tumor tissues (MDTs) from single biopsies. Tumor tissue is mechanically cut into approximately...
- The National Cancer Institute awarded The Rockefeller University $559,596 on July 1, 2026, for research identifying metabolic vulnerabilities in liver cancer under the Cancer Biology Research program (CFDA 93.396). The funded research characterizes mitochondrial metabolites that drive hepatocellular carcinoma and other primary liver cancers through a rapid organelle immunopurification technique (MITO-IP) coupled with liquid chromatography–mass spectrometry. Preliminary work identified marked...
- The National Cancer Institute awarded the Institute For Systems Biology $555,592 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop AI-driven infrastructure for integrating and analyzing cancer datasets and identifying cancer risk factors. The recipient will construct a multi-modal, harmonized resource for the tumor microenvironment featuring an AI-powered spatial search tool. Using spatial datasets from the Human Tumor Atlas Network (HTAN), the...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $391,531 to Yale University to develop technology for directing phosphorylation of specific protein kinase substrates. The goal is to engineer a kinase mutant that can selectively phosphorylate a designer allele of one of its substrates, using knowledge of kinase phosphorylation site specificity. The researchers will establish the feasibility of this approach using the tumor...
- The National Cancer Institute awarded the University of Washington $405,244 on August 13, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and optimize immunopixelseq, a cost-effective spatial immunosequencing platform for precision immuno-oncology research. Immunopixelseq uses 0.6-micrometer-resolution polony gel stamping to produce low-cost arrays compatible with standard Illumina short-read sequencing, enabling spatial co-profiling of whole-tissue...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $3,182,665 (Award Date: September 24, 2025; Completion Date: August 31, 2029) under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. The research will elucidate the mechanisms by which NK cells constrain the effectiveness of ICT, evaluate the contribution of the NKG2D...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $636,345 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to characterize the molecular mechanisms of PI3K activation in cancer using biochemical assays and cryo-electron microscopy imaging. The project focuses on phosphoinositide 3-kinase alpha (PI3KA), one of the most frequently mutated proteins in cancer. Researchers will elucidate how receptor tyrosine kinases and RAS...
- The National Cancer Institute awarded the University of Washington $142,780 on January 23, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical training in careers in basic, clinical, and prevention research relevant to the National Cancer Program. The award funds research addressing antigen-low tumor escape in non-small cell lung cancer through chimeric T cell receptor (ChTCR) therapy. The project develops engineered ChTCRs that fuse a CAR single-chain variable...
- The National Cancer Institute, an office of the Department of Health and Human Services National Institutes of Health, awarded Dana-Farber Cancer Institute, Inc. $657,443 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA315392). The award funds structural and mechanistic studies of the RAS/RAF MAPKINASE pathway to achieve atomic-resolution understanding of how these proteins recognize and interact with one another and how these interactions...
- The National Cancer Institute, a division of the National Institutes of Health under the Department of Health and Human Services, awarded $134,000 to the University of Massachusetts Medical School on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The recipient will conduct research employing genetically engineered mouse models to elucidate mechanisms by which loss of CAMK2B (calcium/calmodulin-dependent protein kinase II beta) promotes metastasis and immune...